Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Insmed Incorporated (INSM)

NASDAQ: INSM · Pharmaceutical Preparations · Bridgewater, NJ

Our rating: Cautious

Cautious reaffirmed at $112.58, moderate conviction, October 30, 2026.

Breaks if: The cautious view is wrong if, within the next six months, both patent invalidations are confirmed on the record — through appellate rulings, company disclosures, or filings — to cover only non-commercial or peripheral claims that do not affect the primary revenue-generating indication AND the next two reported quarterly revenues each show year-over-year growth above 55%; that combination would indicate the core commercial franchise remains legally protected and growth is not decelerating, materially changing the IP-risk and valuation calculus.

Key figures

Market value$31.0B
Revenue, last 12 months$1.5B
Net income, last 12 months−$606M
Free cash flow, last 12 months−$628M
Price to earningsn/a
Free cash flow yield−2.0%
Dividend yield0.0%
Operating margin−37.1%
Return on equity−72.5%
Beta to the S&P 5000.61
Volatility, annualized93.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$524M268.4%$-0.46−$42M
June 30, 2026$425M296.1%$-0.06−$95M
March 31, 2026$306M229.6%$-0.76−$226M
December 31, 2025$264M152.6%$-1.53−$264M
September 30, 2025$142M52.4%$-1.75−$222M
June 30, 2025$107M18.9%$-1.70−$209M
March 31, 2025$93M22.9%$-1.42−$272M
December 31, 2024$104M24.8%$-1.30−$203M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

26 ledger entries and 34 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.